The FDA approved a labeling change to NovoLog (insulin aspart [rDNA origin] injection, from Novo Nordisk) that allows patients with diabetes to use NovoLog in their insulin pump for up to six days. The updated NovoLog label also states that patients should change the infusion set and the infusion set insertion site at least every three days. The previous label allowed for NovoLog to be stored in the pump reservoir for two days and stated that the infusion set and the infusion set insertion site be changed at least every 48 hours. The updated label keeps the same recommendation that NovoLog should be discarded after exposure to temperatures that exceed 37°C (98.6°F).
NovoLog is a rapid-acting insulin indicated in the treatment of diabetes.
For more information call (800) 727-6500 or visit www.novolog.com.